Kronos Bio, Inc. announced that its Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company. The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.03 USD | 0.00% | +7.29% | -17.60% |
Mar. 21 | Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M | MT |
Mar. 21 | Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.60% | 61.9M | |
+0.67% | 42.4B | |
+44.30% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- KRON Stock
- News Kronos Bio, Inc.
- Kronos Bio Announces Resignation of Yasir Al-Wakeel as Head of Corporate Development, Effective from September 15, 2023